Georgia M Parkin1, Jody Corey-Bloom2, Jeffrey D Long3, Chase Snell2, Haileigh Smith2, Elizabeth A Thomas4. 1. Department of Epidemiology, University of California Irvine, Irvine, CA, USA; Institute for Interdisciplinary Salivary Bioscience Research, University of California Irvine, Irvine, CA, USA. Electronic address: gparkin@hs.uci.edu. 2. Department of Neurosciences, University of California San Diego, San Diego, CA, USA. 3. Department of Psychiatry, Department of Biostatistics, University of Iowa, IA, USA. 4. Department of Epidemiology, University of California Irvine, Irvine, CA, USA; Institute for Interdisciplinary Salivary Bioscience Research, University of California Irvine, Irvine, CA, USA.
Abstract
INTRODUCTION: The inclusion of premanifest Huntington's Disease (Pre-HD) subjects in clinical trials necessitates selecting those who are near transition to manifest Huntington's disease (Man-HD). We previously determined that plasma neurofilament light (NfL) levels are significantly correlated with predicted years to Man-HD onset, using established formulae. Recently, a new normalized prognostic index (PIN) score for predicting Pre-HD disease progression has been validated. Our objective was to determine whether plasma NfL levels are similarly associated with PIN score and PIN score-derived years to Man-HD onset (PIN-YTO). METHOD: 112 individuals (46 Pre-HD, 66 Man-HD) underwent blood sample collection and clinical assessment, inclusive of the Symbol Digit Modalities Test and Unified Huntington's Disease Rating Scale Total Motor Score. Plasma NfL levels were measured using a Meso Scale Discovery assay. RESULTS: Pre-HD and Man-HD cohorts differed by age (p < .0001), and CAG repeat number (p = .004), but not education level or gender. Plasma NfL levels were significantly correlated with PIN scores (r = 0.69, p < .0001) and PIN-YTO (r = -0.69, p < .0001). Plasma NfL levels were similarly correlated with predicted years to onset scores determined using Langbehn and colleague's formula (r = -0.68, p < .0001). All significant correlations endured corrections for age and CAG repeat number. A plasma NfL cut-point of <45.0 pg/ml distinguished Pre-HD participants >10 predicted years from Man-HD onset, compared to those ≤10 predicted years. CONCLUSIONS: We have extensively shown that plasma NfL levels are associated with predicted years to manifest HD onset in Pre-HD participants, and present a plasma NfL cut-point that may help exclude far-from-onset Pre-HD patients from clinical trials.
INTRODUCTION: The inclusion of premanifest Huntington's Disease (Pre-HD) subjects in clinical trials necessitates selecting those who are near transition to manifest Huntington's disease (Man-HD). We previously determined that plasma neurofilament light (NfL) levels are significantly correlated with predicted years to Man-HD onset, using established formulae. Recently, a new normalized prognostic index (PIN) score for predicting Pre-HD disease progression has been validated. Our objective was to determine whether plasma NfL levels are similarly associated with PIN score and PIN score-derived years to Man-HD onset (PIN-YTO). METHOD: 112 individuals (46 Pre-HD, 66 Man-HD) underwent blood sample collection and clinical assessment, inclusive of the Symbol Digit Modalities Test and Unified Huntington's Disease Rating Scale Total Motor Score. Plasma NfL levels were measured using a Meso Scale Discovery assay. RESULTS: Pre-HD and Man-HD cohorts differed by age (p < .0001), and CAG repeat number (p = .004), but not education level or gender. Plasma NfL levels were significantly correlated with PIN scores (r = 0.69, p < .0001) and PIN-YTO (r = -0.69, p < .0001). Plasma NfL levels were similarly correlated with predicted years to onset scores determined using Langbehn and colleague's formula (r = -0.68, p < .0001). All significant correlations endured corrections for age and CAG repeat number. A plasma NfL cut-point of <45.0 pg/ml distinguished Pre-HD participants >10 predicted years from Man-HD onset, compared to those ≤10 predicted years. CONCLUSIONS: We have extensively shown that plasma NfL levels are associated with predicted years to manifest HD onset in Pre-HD participants, and present a plasma NfL cut-point that may help exclude far-from-onset Pre-HD patients from clinical trials.
Authors: Jeffrey D Long; Douglas R Langbehn; Sarah J Tabrizi; Bernhard G Landwehrmeyer; Jane S Paulsen; John Warner; Cristina Sampaio Journal: Mov Disord Date: 2016-11-28 Impact factor: 10.338
Authors: Wan Sun; Di Zhou; John H Warner; Douglas R Langbehn; Guenther Hochhaus; Yaning Wang Journal: J Clin Pharmacol Date: 2020-05-16 Impact factor: 3.126
Authors: Filipe B Rodrigues; Lauren M Byrne; Rosanna Tortelli; Eileanoir B Johnson; Peter A Wijeratne; Marzena Arridge; Enrico De Vita; Naghmeh Ghazaleh; Richard Houghton; Hannah Furby; Daniel C Alexander; Sarah J Tabrizi; Scott Schobel; Rachael I Scahill; Amanda Heslegrave; Henrik Zetterberg; Edward J Wild Journal: Sci Transl Med Date: 2020-12-16 Impact factor: 17.956
Authors: Lauren M Byrne; Filipe B Rodrigues; Kaj Blennow; Alexandra Durr; Blair R Leavitt; Raymund A C Roos; Rachael I Scahill; Sarah J Tabrizi; Henrik Zetterberg; Douglas Langbehn; Edward J Wild Journal: Lancet Neurol Date: 2017-06-07 Impact factor: 44.182
Authors: Rachael I Scahill; Paul Zeun; Katherine Osborne-Crowley; Eileanoir B Johnson; Sarah Gregory; Christopher Parker; Jessica Lowe; Akshay Nair; Claire O'Callaghan; Christelle Langley; Marina Papoutsi; Peter McColgan; Carlos Estevez-Fraga; Kate Fayer; Henny Wellington; Filipe B Rodrigues; Lauren M Byrne; Amanda Heselgrave; Harpreet Hyare; Cristina Sampaio; Henrik Zetterberg; Hui Zhang; Edward J Wild; Geraint Rees; Trevor W Robbins; Barbara J Sahakian; Douglas Langbehn; Sarah J Tabrizi Journal: Lancet Neurol Date: 2020-05-26 Impact factor: 44.182